Fig. 1From: Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s diseaseAnalyses workflows. a Re-analysis of simvastatin trial. b Analysis of continual use of statins from multiple AD trials and studies. c Analysis of statin use from the ROS/MAP studies. AD Alzheimer’s disease, MAP Memory Aging Project, ROS Religious Order StudyBack to article page